Here is something unusual in pharmaceutical marketing: Johnson & Johnson now sells two drugs that target the same pathway for the same disease, but through completely different delivery methods. Tremfya (guselkumab) is J&J's established injectable IL-23 blocker. ICOTYDE (icotrokinra) is their new oral IL-23 peptide, developed with Protagonist Therapeutics and approved in March 2026.
For psoriasis patients, this creates a genuinely interesting comparison. Both drugs attack IL-23 signaling, but their molecular designs, dosing schedules, efficacy profiles, and practical implications for daily life are meaningfully different.
Quick Answer
Tremfya delivers slightly higher peak clearance (~80% PASI 90 vs ~70% for ICOTYDE) but requires injections every 8 weeks. ICOTYDE is a daily oral pill with no needles. Both are from J&J, which creates potential advantages for patients who want to transition between the two. If you are doing well on Tremfya and tolerate injections, there may be no reason to switch. If you want to eliminate injections and accept a modest efficacy trade-off, ICOTYDE is the first oral option that makes that possible within the IL-23 class.
ICOTYDE vs Tremfya: Side-by-Side
| Feature | ICOTYDE (Icotrokinra) | Tremfya (Guselkumab) |
|---|---|---|
| Drug Class | Oral IL-23 receptor peptide inhibitor | Injectable IL-23p19 monoclonal antibody |
| Manufacturer | J&J / Protagonist Therapeutics | J&J (Janssen) |
| FDA Approval | March 2026 | July 2017 |
| Dosing | Daily oral tablet | 100mg injection at Weeks 0, 4, then every 8 weeks |
| Injections Per Year | 0 | ~7 (after loading) |
| PASI 90 at Week 16 | ~70% | ~80% |
| PASI 75 at Week 16 | ~85% | ~90% |
| Common Side Effects | Nausea, diarrhea, headache | Injection site reactions, URIs, headache |
| Monitoring | Baseline liver function | TB screening; infection monitoring |
| Annual Cost | ~$15,000–$20,000 | ~$16,000–$22,000 |
Understanding the IL-23 Pathway
Both ICOTYDE and Tremfya disrupt the same fundamental immune pathway. IL-23 is a cytokine produced by dendritic cells and macrophages that activates Th17 cells. Once activated, Th17 cells release downstream inflammatory mediators — primarily IL-17A, IL-17F, and IL-22 — that drive the rapid skin cell turnover and inflammation characteristic of psoriatic plaques.
By blocking IL-23, both drugs interrupt this cascade at a strategic upstream point, preventing the activation of the Th17 axis without the broader immunosuppression associated with older approaches like TNF inhibitors or JAK inhibitors.
The difference is how they block IL-23:
- Tremfya is a large monoclonal antibody that binds the p19 subunit of IL-23, neutralizing the cytokine in circulation before it reaches its receptor.
- ICOTYDE is a small cyclic peptide that binds the IL-23 receptor itself, preventing IL-23 from engaging and initiating signaling.
Both approaches are effective; the receptor-blocking strategy used by ICOTYDE is what enables oral delivery, since the small peptide can survive gastrointestinal transit.
Efficacy: Head-to-Head Numbers
Tremfya's efficacy is well-established through the VOYAGE 1 and VOYAGE 2 trials, plus years of real-world confirmation. At Week 16, Tremfya achieves PASI 90 in approximately 73–80% of patients, with sustained or improving responses through Week 100+.
ICOTYDE's Phase 3 program showed PASI 90 in approximately 70% at Week 16 — a strong result for an oral medication but roughly 10 percentage points below Tremfya. The PASI 75 rates are closer: ~85% for ICOTYDE vs ~90% for Tremfya.
For patients with moderate disease, this gap may be clinically insignificant. For patients with severe, treatment-resistant psoriasis where every percentage point of clearance matters, Tremfya's higher ceiling is relevant.
The J&J Connection: What It Means for Patients
The fact that J&J manufactures both drugs creates some practical advantages:
- Unified patient support: J&J's patient assistance infrastructure covers both medications, potentially simplifying transitions.
- Provider familiarity: Dermatologists who prescribe Tremfya are already well-versed in the IL-23 mechanism, making them comfortable discussing ICOTYDE as an alternative.
- Potential transition protocols: As both drugs target the same pathway, dermatologists may develop streamlined switching protocols.
- Insurance considerations: Plans that cover one J&J IL-23 inhibitor may be more receptive to covering the other, though this varies by insurer.
J&J has not publicly stated whether they intend to position ICOTYDE as a replacement for Tremfya or as a complementary option. In practice, the market will likely stratify by patient preference: injection-tolerant patients may stay on Tremfya, while needle-averse patients migrate to ICOTYDE.
When to Switch from Tremfya to ICOTYDE
Switching from Tremfya to ICOTYDE may make sense if you:
- Are tired of injections and want an oral option
- Experience injection site reactions with Tremfya
- Travel frequently and want to simplify your treatment
- Have developed needle anxiety over time
- Are achieving adequate (but not maximum) clearance and would not lose meaningful ground
Switching may not make sense if you:
- Are achieving near-complete clearance (PASI 100) on Tremfya
- Have severe psoriasis that requires maximum efficacy
- Have GI conditions that could be aggravated by an oral biologic
- Are comfortable with your current injection schedule
If you do switch, discuss timing with your dermatologist. Since Tremfya has a long half-life, you may need a washout period of up to 12 weeks before starting ICOTYDE to avoid overlapping immune suppression.
Side Effects Comparison
ICOTYDE
Predominantly mild GI symptoms: nausea (7.3%), diarrhea (6.1%), headache (5.8%). These typically resolve within the first month. No serious infections or malignancies above placebo rates in Phase 3.
Tremfya
Injection site reactions (~11%), upper respiratory infections (~8%), headache (~7%). Tremfya carries warnings for serious infections including tuberculosis. TB screening is required before starting therapy.
The side effect profiles reflect the delivery difference. Oral drugs tend to cause more GI effects; injectables tend to cause more injection-related and infection-related events.
Cost and Insurance
Annual costs are comparable: ICOTYDE at ~$15,000–$20,000 and Tremfya at ~$16,000–$22,000. Both manufacturers offer patient assistance programs that can reduce commercial copays to $0.
The key insurance difference in 2026 is formulary placement. Tremfya has been on formularies since 2017 and generally faces fewer coverage barriers. ICOTYDE is new, and some insurers may require step therapy (trying Otezla or Sotyktu first) before approving it. This is expected to improve as ICOTYDE gains market traction.
Who Each Treatment Is For
Choose ICOTYDE If:
- You want an oral medication — no needles, no refrigeration, no sharps disposal
- You have moderate psoriasis well-served by ~70% PASI 90
- You are starting IL-23 therapy and prefer the least invasive route
- You want J&J's IL-23 expertise without the injection commitment
Choose Tremfya If:
- You want the highest clearance within J&J's IL-23 portfolio
- You prefer fewer doses per year over daily medication
- You are comfortable with self-injection and want a proven long-term track record
- You have GI sensitivity that could be worsened by an oral drug
Bottom Line
ICOTYDE and Tremfya are sibling drugs — same parent company, same target, different delivery. Tremfya is the slightly more potent option; ICOTYDE is the dramatically more convenient one. There is no universally correct answer. The right choice depends on your priorities, your disease severity, and your comfort with injections.
Use MedSwitcher to compare your out-of-pocket costs for both ICOTYDE and Tremfya, then discuss the trade-offs with your dermatologist. Both are excellent treatments, and having options within the IL-23 class is a genuine win for psoriasis patients.